2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111481
    Flutazolam 27060-91-9 98%
    Flutazolam (MS 4101; Ro 7-6102) is a medicine acts on benzodiazepine receptors of the brain and relieves anxiety or tension.
    Flutazolam
  • HY-111491
    Methiothepin 20229-30-5 98%
    Methiothepin (Metitepine; Ro 8-6837) is a potent and non-selective 5-HT2 receptor antagonist, with pKds of 7.10 (5-HT1A), 7.28 (5HT1B), 7.56 (5HT1C), 6.99 (5HT1D), 7.0 (5-HT5A), 7.8 (5-HT5B), 8.74 (5-HT6), and 8.99 (5-HT7), and pKis of 8.50 (5HT2A), 8.68 (5HT2B), and 8.35 (5HT2C).
    Methiothepin
  • HY-111499
    Emopamil 78370-13-5 98%
    Emopamil is an inhibitor of calcium channel that can reduce ischemia-induced neuronal cell damage.
    Emopamil
  • HY-111514
    4-(6-Bromo-2-benzothiazolyl)benzenamine 566169-97-9 ≥98.0%
    4-(6-Bromo-2-benzothiazolyl)benzenamine is a β-amyloid PET (positron emission tomography) tracer that can be used in the diagnosis of neurological diseases, such as Alzheimer's and Down's syndrome.
    4-(6-Bromo-2-benzothiazolyl)benzenamine
  • HY-111528
    CGP 43487 146388-56-9 98%
    CGP 43487 is a NMDA receptor antagonist. CGP 43487 significantly affects the gross structural characteristics of the developing dentate gyrus.
    CGP 43487
  • HY-111935
    3,3'-Diethyl-9-methylthiacarbocyanine iodide 3065-79-0 98%
    3,3'-Diethyl-9-methylthiacarbocyanine iodide is a cyanine dye, also a tau aggregation inhibitor, with an IC50 value of 0.28 μM for tau. 3,3'-Diethyl-9-methylthiacarbocyanine iodide can cause misfunction of the microtubule cytoskeleton. 3,3'-Diethyl-9-methylthiacarbocyanine iodide can be used for researching Alzheimer’s disease.
    3,3'-Diethyl-9-methylthiacarbocyanine iodide
  • HY-112095
    EVT-101 free base 627525-33-1 98%
    EVT-101 free base is a GluN2B antagonist. EVT-101 free base binds at the same GluN1/GluN2B dimer interface as Ifenprodil (HY-12882). EVT-101 free base inhibits calcium influx in chicken-derived cells, with an EC50 of 22 nM. EVT-101 can be used in the research of brain disorders.
    EVT-101 free base
  • HY-112263
    ORL1 antagonist 1 1174985-59-1 98%
    ORL1 antagonist 1 is an opioid receptor-like 1 (ORL1) antagonist with an IC50 of 61 nM.
    ORL1 antagonist 1
  • HY-112270
    Glutaminyl Cyclase Inhibitor 2 1884546-29-5 98%
    Glutaminyl Cyclase Inhibitor 2 is a glutaminyl cyclase inhibitor with an IC50 of 1.23 μM.
    Glutaminyl Cyclase Inhibitor 2
  • HY-112313
    CTS-21166 1226777-95-2 98%
    CTS-21166 is a blood-brain barrier-permeable and orally active BACE1 inhibitor. CTS-21166 reduces brain Aβ levels. CTS-21166 can be used in the research of Alzheimer's disease.
    CTS-21166
  • HY-112320
    UCSF34 14862-80-7 98%
    UCSF34 (Compound 54) is a Haloperidol (HY-14538) analogue. UCSF34 binds to the human D2L receptor, with an estimated pKi of 7.49. UCSF34 can be used in the research of schizophrenia.
    UCSF34
  • HY-112336
    Aloisine RP106 496864-15-4 98%
    Aloisine RP106 (compound 38) is a potent inhibitor of Cdk1/cyclin B, Cdk5/p25, and GSK3 with IC50s of 0.70µM, 1.5µM, 0.92 µM, respectively.
    Aloisine RP106
  • HY-112426
    LAU159 2055050-87-6 98%
    LAU159 is a functionally selective positive modulator of α1β3 GABA(A) receptor with an EC50 of 2.2 μM.
    LAU159
  • HY-112482
    ABT-702 214697-26-4 99.61%
    ABT-702 is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research.
    ABT-702
  • HY-112567
    TRR469 1394867-58-3 98%
    TRR469 is a positive allosteric modulator of the A1 adenosine receptor (A1AR). TRR469 significantly increases the affinity of 2-chloro N(6)-cyclopentyladenosine (CCPA) for A₁AR, increasing the number of receptors recognized by the agonist radioligand [³H]-CCPA. TRR469 shows significant effects in both anxiety and pain models. TRR469 can be used to study anxiety disorders and pain management.
    TRR469
  • HY-112652
    ACS-67 1088434-86-9 98%
    ACS-67 is a hydrogen sulphide-releasing derivative of Latanoprost acid. ACS-67 has the potential for glaucoma research.
    ACS-67
  • HY-112828
    LEI105 1800327-36-9 98%
    LEI105 is a potent, highly selective and reversible dual diacylglycerol lipase (DAGL)-α/DAGL-β inhibitor. LEI105 reduces 2-arachidonoylglycerol levels in Neuro2A cells. LEI105 also reduces cannabinoid CB1-receptor-mediated short-term synaptic plasticity in a mouse hippocampal slice model. LEI105 is promising for research of diseases, such as obesity, related metabolic disorders and neuroinflammation.
    LEI105
  • HY-112840
    ST3932 1246018-21-2 98%
    ST3932 is a metabolite of ST1535, acts as an antagonist of adenosine A2A receptor, with Kis of 8 nM and 33 nM for A2A and A1 receptors, respectively.
    ST3932
  • HY-113037
    (E/Z)-Farnesyl pyrophosphate 13058-04-3 98%
    (E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis.
    (E/Z)-Farnesyl pyrophosphate
  • HY-113040
    (17S,18R)-Epoxyeicosatetraenoic acid 131339-23-6 98%
    17(18)-EpETE, a 17(18)-epoxyeicosatetraenoic acid, is a metabolize of Eicosapentaenoic acid (HY-B0660). 17(18)-EpETE stimulates K+ outward currents. 17(18)-EpETE has relaxing effects on arterial and airway smooth muscles in human lung.
    (17S,18R)-Epoxyeicosatetraenoic acid
Cat. No. Product Name / Synonyms Application Reactivity